Parkinson's Disease Psychosis Market is Expected to Witness Steady Growth by 2036, Driven by Rising Disease Burden and Emerging Novel Therapies | DelveInsight

Parkinson's Disease Psychosis Market is experiencing steady growth, driven by the rising prevalence of Parkinson's disease, increasing recognition of non-motor symptoms, improved diagnosis rates of PDP, and growing adoption of targeted treatment options. Furthermore, the development of emerging therapies, including OV4071 by Ovid Therapeutics, and ongoing advances in understanding psychosis-related neurological pathways are expected to support market expansion throughout the forecast period.
DelveInsight, a leading market research and consulting firm, announces the release of its latest report, "Parkinson's Disease Psychosis Market Insights, Epidemiology, and Market Forecast-2036." The report provides an in-depth understanding of Parkinson's Disease Psychosis, including historical and forecasted epidemiology, current treatment practices, emerging therapies, market trends, market size, market share, and competitive landscape across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Parkinson's Disease Psychosis Market

*
The Parkinson's Disease Psychosis market size across the 7MM is expected to grow steadily during the forecast period 2022-2036.

*
The total Parkinson's Disease Psychosis market size in the 7MM was approximately USD 738 million in 2025 and is projected to reach nearly USD 1.7 billion by 2036.

*
In 2025, the total diagnosed prevalent cases of Parkinson's Disease Psychosis across the 7MM were approximately 900 thousand cases and are expected to increase through 2036.

*
The United States accounted for nearly 50% of the total diagnosed prevalent cases of Parkinson's Disease Psychosis in the 7MM in 2025.

*
EU4 and the United Kingdom collectively represented approximately 40% of the total diagnosed prevalent cases, while Japan accounted for nearly 10%.

*
Germany accounted for the highest diagnosed prevalent Parkinson's Disease Psychosis cases among EU4 and the UK, with approximately 130 thousand cases in 2025.

*
Japan reported approximately 75 thousand diagnosed prevalent Parkinson's Disease Psychosis cases in 2025, with patient numbers anticipated to increase throughout the forecast period.

*
Leading Parkinson's Disease Psychosis companies include Acadia Pharmaceuticals and Ovid Therapeutics, among others.

*
Key Parkinson's Disease Psychosis therapies include NUPLAZID (pimavanserin), Quetiapine, Clozapine, and emerging candidate OV4071.

Keen to know more about the market? Request our sample page at Parkinson's Disease Psychosis Market Report. [https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment]

Key Factors Driving the Parkinson's Disease Psychosis MarketIncreasing Prevalence of Parkinson's Disease

The growing aging population worldwide is contributing to a rising prevalence of Parkinson's disease. As disease duration increases, a larger proportion of patients develop psychosis-related symptoms, creating significant demand for effective treatment options.

Rising Recognition of Non-Motor Symptoms

Healthcare providers are increasingly recognizing Parkinson's Disease Psychosis as a major non-motor complication associated with reduced quality of life, increased healthcare utilization, and greater caregiver burden. Improved diagnosis is expected to support market growth.

Growing Adoption of Targeted Therapies

The availability of NUPLAZID, the only FDA-approved therapy specifically indicated for hallucinations and delusions associated with Parkinson's Disease Psychosis, has significantly improved treatment standards and increased awareness of disease-specific therapeutic approaches.

Emergence of Novel Pipeline Therapies

Emerging therapies targeting new neurological pathways are expected to provide additional treatment options. The development of OV4071 and other innovative therapies could potentially address unmet needs related to efficacy, safety, and tolerability.

Parkinson's Disease Psychosis Competitive Landscape

Several Parkinson's Disease Psychosis therapies are currently used in clinical practice, including NUPLAZID (pimavanserin), Quetiapine, and Clozapine. NUPLAZID remains the only FDA-approved therapy specifically indicated for hallucinations and delusions associated with Parkinson's Disease Psychosis and continues to dominate the treatment market. Quetiapine and Clozapine are frequently used off-label based on physician preference and patient-specific considerations.

The emerging Parkinson's Disease Psychosis pipeline includes OV4071 (Ovid Therapeutics), an oral direct KCC2 activator planned for clinical evaluation in psychosis associated with Parkinson's disease and Lewy body dementia. The therapy aims to address significant unmet needs in neuropsychiatric symptom management and may provide a differentiated treatment approach.

Discover more about therapies set to grab major Parkinson's Disease Psychosis market share @ Parkinson's Disease Psychosis Treatment Landscape. [https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment]

Recent Developments in the Parkinson's Disease Psychosis Market

*
In September 2023, Acadia Pharmaceuticals announced that the US FDA updated the NUPLAZID label to clarify its use in treating hallucinations and delusions associated with Parkinson's Disease Psychosis without introducing new safety findings.

*
Ovid Therapeutics continues advancing OV4071, an oral direct KCC2 activator, for psychosis associated with Parkinson's disease and Lewy body dementia.

*
Ongoing research efforts continue to evaluate novel approaches to managing psychosis while minimizing deterioration of motor function in Parkinson's disease patients.

What is Parkinson's Disease Psychosis?

Parkinson's Disease Psychosis (PDP) is a serious neuropsychiatric complication of Parkinson's disease characterized by hallucinations, delusions, illusions, and other psychotic symptoms. Visual hallucinations are the most common manifestation, although patients may also experience auditory hallucinations, depression, anxiety, and cognitive impairment. PDP is associated with increased morbidity, reduced quality of life, longer nursing home stays, and greater caregiver burden.

Parkinson's Disease Psychosis Epidemiology Segmentation

The Parkinson's Disease Psychosis epidemiology section provides insights into historical and forecasted patient populations across the 7MM and includes:

*
Total Diagnosed Prevalent Cases of Parkinson's Disease

*
Total Diagnosed Prevalent Cases of Parkinson's Disease Psychosis

*
Country-specific Diagnosed Prevalent Cases of Parkinson's Disease Psychosis

*
Age-related Disease Burden Trends

*
Forecasted Epidemiology Trends Across the 7MM

Scope of the Parkinson's Disease Psychosis Market Report

*
Therapeutic Assessment: Current and Emerging Parkinson's Disease Psychosis Therapies

*
Parkinson's Disease Psychosis Market Dynamics: Market Drivers, Barriers, and Opportunities

*
Key Companies: Acadia Pharmaceuticals, Ovid Therapeutics, and others

*
Key Therapies: NUPLAZID (Pimavanserin), Quetiapine, Clozapine, OV4071, and others

*
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies

*
Market Size, Market Share, Industry Trends, and Forecast Analysis

*
KOL Perspectives, Analyst Views, Market Access, and Reimbursement Assessment

To know more about Parkinson's Disease Psychosis companies working in the treatment market, visit @ Parkinson's Disease Psychosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment]Table of Contents

*
Parkinson's Disease Psychosis Market Report Introduction

*
Executive Summary for Parkinson's Disease Psychosis

*
SWOT Analysis of Parkinson's Disease Psychosis

*
Parkinson's Disease Psychosis Patient Share (%) Overview at a Glance

*
Parkinson's Disease Psychosis Market Overview at a Glance

*
Parkinson's Disease Psychosis Disease Background and Overview

*
Parkinson's Disease Psychosis Epidemiology and Patient Population

*
Country-Specific Patient Population of Parkinson's Disease Psychosis

*
Parkinson's Disease Psychosis Current Treatment and Medical Practices

*
Parkinson's Disease Psychosis Unmet Needs

*
Parkinson's Disease Psychosis Emerging Therapies

*
Parkinson's Disease Psychosis Market Outlook

*
Country-Wise Parkinson's Disease Psychosis Market Analysis (2022-2036)

*
Parkinson's Disease Psychosis Market Access and Reimbursement

*
Parkinson's Disease Psychosis Market Drivers

*
Parkinson's Disease Psychosis Market Barriers

*
Parkinson's Disease Psychosis Appendix

*
Parkinson's Disease Psychosis Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-psychosis-market-is-expected-to-witness-steady-growth-by-2036-driven-by-rising-disease-burden-and-emerging-novel-therapies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.